Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-2 vs MK-677 (Ibutamoren)
An educational, source-based comparison of GHRP-2 and MK-677 (Ibutamoren) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide that activates the ghrelin/GHS-R1a receptor, stimulating endogenous GH release. Compared to Ipamorelin, GHRP-2 produces a stronger GH pulse but also modestly elevates cortisol, prolactin, and appetite.
- GH release in adult GH deficiency
- Appetite stimulation in cachexia models
- Diagnostic GH stimulation testing
- • Not FDA-approved.
- • Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- • Prohibited by WADA.
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHRP-2 | GHRP-2 stimulates GH release in healthy and GH-deficient adults | Journal of Clinical Endocrinology & Metabolism | 1997 | Established robust GH response after subcutaneous administration. |
| MK-677 (Ibutamoren) | MK-677 increases GH and IGF-1 in elderly adults | Annals of Internal Medicine | 2008 | Two-year RCT showing sustained IGF-1 elevation and lean mass increase. |
Side-effect & safety grid
- Not FDA-approved.
- Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- Prohibited by WADA.
- Not FDA-approved.
- Insulin resistance and fluid retention reported.
- Banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHRP-2 vs MK-677 (Ibutamoren) — Key differences
- Class: GHRP-2 is classified as Growth Hormone Axis, while MK-677 (Ibutamoren) is Growth Hormone Axis · Small Molecule.
- Primary research focus: GHRP-2 — gh release in adult gh deficiency; MK-677 (Ibutamoren) — gh/igf-1 elevation in adults.
- Tag: Growth hormone vs Growth hormone · Oral.